Investor Kit

Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
11/22/17
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
02/14/18SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/18SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/18SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/18SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/09/18SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
02/22/18Pacira Pharmaceuticals Announces Timing for 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2017 financial results before the open of the U.S. markets on Wednesday February 28, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. ... 
Printer Friendly Version
02/16/18Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference
PARSIPPANY, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website f... 
Printer Friendly Version
02/15/18Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
Company working with FDA toward April 6, 2018 PDUFA date PARSIPPANY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), announced today that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce regional analgesia. The committee’s feedback will be consider... 
Printer Friendly Version
02/14/18Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15 PARSIPPANY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting to review the company’s supplemental New Drug Application seeking approval of EXPAREL® (bupivacaine liposome injecta... 
Printer Friendly Version
02/12/18FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
-- Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15 -- PARSIPPANY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has posted briefing materials for the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) meeting that will review the company’s supplemental New Drug Application seeking expansion of the current EXPAREL® (bupivacaine liposome injectab... 
Printer Friendly Version
01/08/18WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures
Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals PARSIPPANY, N.J. and ATLANTA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- WellStar Health System, the largest health system in Georgia, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint commitment to address opioid use and dependence following surgery. Through a comprehensive opioid minimization strategy, the organizations will work togeth... 
Printer Friendly Version
01/04/18Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million
-- EXPAREL sales of $282.9 million driven by Phase 4 data, education and strategic partnerships -- PARSIPPANY, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary unaudited total revenues and EXPAREL® (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and full-year 2017. “2017 was an exciting year marked by solid revenue growth and multiple major milestones that support our mission of improving pat... 
Printer Friendly Version
01/03/18Pacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, Inc. is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference at 2:00 PM PT (5:00 PM ET) on Tuesday, January 9, 2018 in San Francisco, CA. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at inve... 
Printer Friendly Version
12/14/17Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients
Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals PARSIPPANY, N.J. and EVANSTON, Ill., Dec. 14, 2017 (GLOBE NEWSWIRE) -- The Illinois Surgical Quality Improvement Collaborative (ISQIC), a nationally recognized partnership of 56 Illinois hospitals, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced an initiative to jointly develop programs and resou... 
Printer Friendly Version
12/08/17Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
PARSIPPANY, N.J., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference at 11:30 AM ET on Thursday, December 14, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archiv... 
Printer Friendly Version
>> Access Older Press Releases